Eckard Weber
Partner @ Domain Associates
San Diego, United States
Eckard Weber is a Series A investor at Domain Associates in San Diego focused on Biotechnology and Health Care. Eckard Weber is aVenture Partner at Canaan Partners and he is also an Advisory Partner at Domain Associates. He holds a B.S. from Kolping College in Germany and an M.D. from the University of Ulm Medical School in Germany.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Eckard Weber invests in
Stages Eckard Weber invests in
Countries Eckard Weber invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (43%)
- Health Care 5 (36%)
- Medical 3 (21%)
- Pharmaceutical 3 (21%)
- Therapeutics 2 (14%)
Stage
- Series A 5 (36%)
- Series B 4 (29%)
- Series C 2 (14%)
- Funding Round 2 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias. | $80M / Series C / Aug 24, 2015 | ||
| Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, andmanufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com. | $13.5M / Series B / Jan 10, 2014 | ||
| Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, andmanufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com. | $38.5M / Series B / Dec 17, 2013 | ||
| Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias. | $26.6M / Series B / Aug 27, 2013 | ||
| Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associatedinfectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey. | $31M / Series B / Sep 29, 2010 | ||
| Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting importantcyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients.Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California. | $5M / Apr 15, 2010 | ||
| Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias. | $9M / Series A / Mar 16, 2010 | ||
| Sequel Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes novel and clinical-stage drug candidates for patients with cardiovascular disease. The company was founded in 2007 and is based in San Diego, California. | $20M / Series A / Sep 27, 2007 | ||
| Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associatedinfectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey. | $31M / Series A / Aug 02, 2007 | ||
| Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting importantcyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients.Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California. | $40M / Series A / Mar 15, 2007 | ||
| See all 14 investments → | |||
Co-Investors
About Domain Associates
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices,while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
Domain Associates Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brian Dovey
Partner
|
|||
Brian Halak
Partner
|
|||
Dennis Podlesak
Venture Capitalist
|
|||
|
Eckard Weber
Partner
|
|||
Jesse I. Treu
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Eckard Weber invest in?
Eckard Weber invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Eckard Weber?
Public channels for Eckard Weber include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Eckard Weber last invest?
The most recent investment recorded for Eckard Weber closed in Aug 2015. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
